What changed today in Regulatory: 1 recall record
Every new official record on the Pharmacy, Compounding & Regulatory Intelligence desk since this morning, each linked to its primary source.
Automated from official records1 source1 min read
Drug shortages
FDA drug-shortage determinations and their effect on supply, compounding and patient access.
Emerging
- Editorial attention
- Emerging
- Tracked this week
- 1
- Sources this week
- 1
- Last activity
- 2 days ago
Signal strength reflects editorial attention across tracked sources — not medical certainty or strength of evidence.
- Pending editorial review
A system check is an automated check of the official sources, not a human review. An editorial review is recorded only when one of our editors has reviewed the page.
Drug shortages at a glance
- About this topic
- FDA drug-shortage determinations and their effect on supply, compounding and patient access.
- Current status
- No editor-reviewed status summary yet. The official records below update automatically.
- Last updated
- Primary sources
- Latest official record: Medline Updates Customers and Patients on Repair and Replace Program for Recall of Medline Brand Beds, Rails, Mattresses and Accessories (opens the source in a new tab) (U.S. Food and Drug Administration, Nov 13, 2026)
- Key facts from tracked records
- 9 NPHLA briefings on this topic
What’s the latest on Drug shortages?
9 totalWhat changed today in Metabolic: 8 trial updates
Every new official record on the Metabolic & Weight-Loss Intelligence desk since this morning, each linked to its primary source.
Automated from official records9 sources1 min read
What changed today in Metabolic: 5 trial updates, 2 drug-shortage updates, 1 new study
Every new official record on the Metabolic & Weight-Loss Intelligence desk since this morning, each linked to its primary source.
Automated from official records9 sources1 min read
What changed today in Metabolic: 3 trial updates, 2 new studies
Every new official record on the Metabolic & Weight-Loss Intelligence desk since this morning, each linked to its primary source.
Automated from official records8 sources1 min read
How a drug’s place on FDA’s shortage list changes the compounding rules
When FDA lists a drug as in shortage, some federal limits on compounding copies of that drug stop applying; when FDA resolves the shortage, they return. Here is how that works for 503A pharmacies and 503B outsourcing facilities.
AI-assisted · Editor reviewed6 sources2 min read
503A or 503B? How the two federal compounding pathways differ — and why it mattered for GLP-1 medicines
Federal law gives compounders two routes, with different rules on prescriptions, quality standards, oversight and copies of approved drugs. Here is how they compare, using GLP-1 compounding as the worked example.
AI-assisted · Editor reviewed6 sources3 min read
What changed today in Regulatory: 1 new study
Every new official record on the Pharmacy, Compounding & Regulatory Intelligence desk since this morning, each linked to its primary source.
Automated from official records1 source1 min read
What changed today in Metabolic: 4 new studies, 3 trial updates
Every new official record on the Metabolic & Weight-Loss Intelligence desk since this morning, each linked to its primary source.
Automated from official records9 sources1 min read
What do the official records show?
Primary sources and peer-reviewed research- Medline Updates Customers and Patients on Repair and Replace Program for Recall of Medline Brand Beds, Rails, Mattresses and Accessories (opens the source in a new tab)
On October 14, 2026, Medline initiated a product recall, market exit and discontinuation of all Medline Brand beds, rails, mattresses, and accessories (e.g., pendants and motor boxes) due to a potential fire hazard and entrapment risk, which may result in patient injury or dea…
- New trial registered: ERCG vs Intensive Lifestyle Intervention for Weight Regain After GLP-1 RA Discontinuation (opens the source in a new tab)
Not applicable, Affiliated Hospital to Academy of Military Medical Sciences. Conditions: Obesity & Overweight. Interventions: Endoscopic Radial Compression Gastroplasty (ERCG); Intensive Lifestyle Intervention (ILI). Investigational: trial-stage therapies are not approved for …
- Drug shortage update: Liraglutide Injection — Current (opens the source in a new tab)
Liraglutide, Injection, 6 mg/1 mL (NDC 0143-9144-02). Company: Hikma Pharmaceuticals USA, Inc.
- Drug shortage update: Liraglutide Injection — Current (opens the source in a new tab)
Liraglutide, Injection, 6 mg/1 mL (NDC 0143-9144-03). Company: Hikma Pharmaceuticals USA, Inc.
- Weight Maintenance Following Discontinuation of Semaglutide in an Adolescent with Antipsychotic-Associated Weight Gain: A Case Report (opens the source in a new tab)
- Operational Workflows and Decision Making Processes in Hospital Pharmacy Services During Drug Shortages: A Scoping Review (opens the source in a new tab)
- Preventing Weight Regain After Glucagon-Like Peptide‑1 Therapy Discontinuation: A Pilot Randomized Controlled Trial (opens the source in a new tab)
- New trial registered: Tapered Versus Abrupt Discontinuation of Semaglutide After Treatment of Recurrent Weight Gain or Suboptimal Response Following Metabolic and… (opens the source in a new tab)
Phase 4, General Committee of Teaching Hospitals and Institutes, Egypt. Conditions: Morbid Obesity. Interventions: Semaglutide weekly injection; Placebo. Investigational: trial-stage therapies are not approved for the use studied.